The Impact of Iclusig: Access Program May Have Important Implications For Personalized Medicine
This article was originally published in RPM Report
FDA’s decision to seek the withdrawal of Ariad’s Iclusig prompted concerns about greater caution by the agency in the “Breakthrough” era. A more important implication, however, may be in whether the continued access program succeeds in meeting demand for the product. That could become a model for future development of ever-more personalized cancer treatment regimens.